Navigation Links
John McKearn, Ph.D., Promoted to Managing Director of RiverVest Venture Partners
Date:5/3/2011

ST. LOUIS, May 3, 2011 /PRNewswire/ -- RiverVest Venture Partners®, a venture capital firm investing in emerging medical technology and biopharmaceutical companies, today announced that John McKearn, Ph.D., has been promoted to Managing Director.  

Dr. McKearn joined RiverVest as Venture Partner in 2008, bringing extensive scientific and operational expertise in pharmaceutical research and development as former president and CEO of Kalypsys, Inc.; head of discovery research for Pharmacia and Searle; and senior scientist with E.I. DuPont de Nemours and Company.

"John has been a valuable addition to the RiverVest team and we are pleased to promote him," said Jay Schmelter, RiverVest Managing Director. "His deep knowledge of pharmaceutical research and development is instrumental in enhancing the drug development programs of our portfolio companies and securing important venture capital financing opportunities."

Most recently, Dr. McKearn helped originate and structure a $38.5 million Series B financing for Otonomy, Inc., a clinical stage biopharmaceutical company developing novel drug therapies for disorders of the inner and middle ear. The deal, which closed in August 2010, was co-led by Novo Ventures and RiverVest Venture Partners, and joined by TPG Biotech, Domain Associates and Avalon.

"This is an exciting time for RiverVest," said Dr. McKearn. "As a team, we are uniquely positioned in a marketplace that has been defined in recent years as harsh, frenetic and out of balance. We continue to leverage our deep operating experience to attract and shape promising biopharmaceutical opportunities and build value for our portfolio companies."  

Dr. McKearn holds a Ph.D. in immunology from the University of Chicago and a B.S. in biology from Northern Illinois University. He currently serves as a member of the board of directors for Otonomy, Inc., and has served on the boards of IDM Pharma, Inc. (acquired by Takeda), Epimmune and Keel Pharmaceuticals, Inc.  Dr. McKearn holds more than 50 patents and numerous patent applications, primarily in the areas of cancer treatment and inflammatory disease.

About RiverVest Venture Partners

RiverVest is a venture capital firm focused on identifying and shaping early-stage life science companies to create significant shareholder value. With hands-on, high-level expertise and financial resources, RiverVest supports entrepreneurs by helping them achieve near-term objectives that position their companies for exit. For more information, please visit www.rivervest.com.


'/>"/>
SOURCE RiverVest Venture Partners
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ChromaDex Appoints Curtis Lockshin, Ph.D., to its Board of Directors
2. Heiner Dreismann, Ph.D., Former President of Roche Molecular Systems, Joins the HistoRx Board of Directors
3. WaferGen Names Gary P. Schroth, Ph.D., as New SVP, Genomics Research and Applications
4. Fibrocell Science, Inc. Names Biotechnology and Genetic Research Expert Stefan Gruenwald, M.D., Ph.D., to Scientific Advisory Board
5. American Humane Association Announces Joy Mench, Ph.D., Joins the Scientific Advisory Committee of the American Humane Certified® Farm Animal Program
6. Melissa Kemp, Ph.D., Wins the Council for Systems Biology in Boston (CSB2) Award Sponsored by Merrimack Pharmaceuticals, Inc.
7. ChemoCentryx President and CEO, Thomas J. Schall, Ph.D., Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist in Northern California
8. Fate Therapeutics Appoints Tom Novak, Ph.D., as Vice President of Research and Drug Discovery
9. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
10. 5th Annual Szent-Gyorgyi Prize for Progress in Cancer Research Awarded to Peter K. Vogt, Ph.D., The Scripps Research Institute
11. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... ... May 24, 2017 , ... ... as treasurer for the Mid-Atlantic chapter of the Healthcare Businesswomen’s Association ... , The HBA Mid-Atlantic chapter board meets in person once each quarter and ...
(Date:5/24/2017)... ... May 23, 2017 , ... ... permanent modular buildings, announced the launch of the Mobile Big Room. This ... to help support on-site teamwork and collaboration. , The Mobile Big Room ...
(Date:5/24/2017)... ... May 24, 2017 , ... Patient Monitoring ... with Wi-Fi connectivity to reduce the amount of wiring in a healthcare facility ... compact mobile devices including infusion pumps, heart and hypertension monitoring, glucose monitoring, and ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... cloud-based file transfer solution that makes it easy for organizations to send and ... worry about cumbersome FTP software or email file size limitations. , Using ...
Breaking Biology Technology:
(Date:3/23/2017)... Research and Markets has announced the addition ... - Industry Forecast to 2025" report to their offering. ... The Global Vehicle ... around 8.8% over the next decade to reach approximately $14.21 billion ... estimates and forecasts for all the given segments on global as ...
(Date:3/22/2017)... LIVERMORE, Calif. , March 21, 2017 ... recognition analytics company serving law enforcement agencies, announced today ... Sheridan as director of public safety business development. ... of diversified law enforcement experience, including a focus on ... Vigilant. In his most recent position, Mr. Sheridan served ...
(Date:3/16/2017)... Germany , March 16, 2017 CeBIT 2017 - Against identity ... Continue Reading ... Used combined in one project, multi-biometric solutions provide ... Used ... Systems) ...
Breaking Biology News(10 mins):